Tumor Associated Macrophages News and Research

RSS

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

Two analgesic drugs may one day be repurposed as anti-tumor therapies

Peripheral afferent neurons - nerves that send signals from all areas of the body to the central nervous system (brain and spinal cord) - are known to infiltrate and grow within malignant bone tumors called osteosarcomas, often accompanied by severe pain.

29 Oct 2025

Amino acid metabolism shapes the tumor immune microenvironment and therapy response

The tumor microenvironment is not just a site of cancer growth—it is a high-stakes metabolic contest where tumor and immune cells vie for limited resources.

17 Aug 2025

Electrophysiology-based strategies enhance cancer immunotherapy

Tumor electrophysiological abnormalities, characterized by membrane potential dysregulation, ion channel network remodeling, and microenvironmental signaling interactions, are critical drivers of malignancy.

17 Aug 2025

Targeting lactate metabolism offers new avenues for cancer treatment

Lactic acid (LA) has transitioned from being perceived as a mere glycolytic waste product to a pivotal regulator of tumor-immune crosstalk.

5 Aug 2025

T cell senescence shapes cancer prognosis and immunotherapy response

T cell senescence occurs in the TME, affecting cancer prognosis and immunotherapy efficacy. The TME induces T cell senescence through multiple pathways, including persistent stimulation by tumor-associated antigens, metabolic pathway alterations, activation of chronic inflammatory responses, proliferation of immunosuppressive cells, and T cell damage caused by tumor radiotherapy and chemotherapy.

31 Jul 2025

Metabolic enzyme PHGDH found to play a surprising role in breast cancer immunity

Macrophages are immune cells with a split personality: some fight tumors, while others help them grow. In breast cancer, most macrophages fall into the latter camp—dubbed M2-like—fueling tumor progression and dampening immune responses.

7 Jul 2025

Blocking key immune cells could make prostate cancer treatable

Scientists have revealed how certain immune cells may be quietly helping prostate cancer grow - and how blocking them could help the body fight back.

3 Jul 2025

Targeting the tumor microenvironment to improve osteosarcoma outcomes

The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance.

26 Jun 2025

Myeloid cells shape tumor microenvironments and influence cancer progression

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments (TME), influencing tumor progression, immune evasion, and therapeutic resistance.

3 Jun 2025

lncRNAs shape the tumor microenvironment and drive cancer development

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, extracellular matrix (ECM), cytokines, and growth factors, all interacting to influence tumorigenesis, progression, and metastasis.

24 Apr 2025

Blocking an enzyme to overcome immunotherapy resistance in melanoma patients

About 65% of melanoma patients do not respond to immunotherapy. New work by the team of Prof. Max Mazzone (VIB-KU Leuven Center for Cancer Biology) discovered that an enzyme called HPGDS (expressed in a specific subset of macrophages), plays a key role in immunotherapy resistance.

7 Apr 2025

Study elucidates mechanism behind bacterial cancer therapy

A research team led by Prof. Liu Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. Xiao Yichuan from the Shanghai Institute of Nutrition and Health of CAS elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain.

3 Mar 2025

New approach to treating ependymoma with leukemia drug

Rakesh Jain PhD, Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk Cook Professor of Radiation Oncology at Harvard Medical School, is senior author of a new study in PNAS, Targeting EPHB2/ABL1 Restores Anti-Tumor Immunity in Preclinical Models of Ependymoma.

23 Jan 2025